The Multiple Myeloma Patient Journey

Time Commitment:	3 hours 15 minutes over 6 weeks
Target Professions:	MD, DO, Nurse, Nurse Practitioner, Pharmacist, Physician Assistant
Target Specialties:	Hematology, Hematology/Oncology, Oncology
Credits Available:	3.25 AMA PRA Category 1 Credit™

• The Multiple Myeloma Patient Journey - Baseline Assessment

  This assessment will provide a baseline measure of your knowledge of best practices in relapsed/refractory multiple myeloma treatment.

• Module 1: Treatment Selection and Sequencing in Early Relapse

  This case will discuss the journey of a 56-year-old male patient with newly diagnosed multiple myeloma who, after 2.5 years of maintenance therapy, relapses and works with his hematology/oncology specialist to select his next treatment.

• Module 2: Treatment Selection and Sequencing in Late Relapse

  This case will review the journey of a 41 year old male patient with quadruple-refractory multiple myeloma who works with his hematology/oncology specialist to select the next steps in his MM treatment journey.

• Final Assessment: The Multiple Myeloma Patient Journey

  This post-activity assessment will ascertain the knowledge gained as a result of your participation in this initiative.

• Lessons Learned and Ongoing Challenges

  The group will discuss key points from each of the preceding modules, as well as group challenge submissions and general comments.

• Discussion of Group Challenges and Action Plans

  The group will discuss the group challenges, their action plans, and barriers to implementation while receiving real-time feedback from the group leader and other group members.

• Case Study 1 - Maeve, a 62-year-old African American female

  This group case discussion will discuss treatment selection and sequencing challenges for a patient with R-ISS, stage II, IgG lambda multiple myeloma (MM) in the early relapse setting.

• Case Study 2 - Akamu, a 57-year-old Polynesian male

  In this group activity, learners will discuss treatment selection and sequencing challenges in the case of a patient with R-ISS, stage II, hyperdiploid multiple myeloma (MM).

• Your Action Plan in Multiple Myeloma

  In light of the information reviewed and discussed during this program, can you share an action plan that you will implement to improve the outcomes for your patients with relapsed or refractory multiple myeloma (RRMM).

Requirements:
Group leaders should be highly proficient in the management and treatment of relapsed/refractory multiple myeloma, and have a working knowledge of working in collaboration with other healthcare professionals. Group leaders include clinicians involved in specialized care for patients with multiple myeloma (such as academic-based clinicians), clinical research studies related to the treatment of relapsed/refractory multiple myeloma, and associated clinical teaching. Apply Now